<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00523237</url>
  </required_header>
  <id_info>
    <org_study_id>RAL-eve study</org_study_id>
    <nct_id>NCT00523237</nct_id>
    <nct_alias>NCT00627939</nct_alias>
  </id_info>
  <brief_title>RAL-eve Study: Raltegravir Substitution Study</brief_title>
  <official_title>Raltegravir Substitution for Enfuvirtide in Patients Suffering From Injection Site Reactions (ISRs): The Raleve Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to:

        -  Provide raltegravir to subjects with HIV and an undetectable viral load who are
           experiencing injection site reactions (ISR) to Enfuvirtide,

        -  Monitor the safety and efficacy of raltegravir, and

        -  Assess the change in quality of life in patients who have switched from Enfuvirtide to
           raltegravir
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We enrolled virologically suppressed HIV-1 infected patients with injection site reactions
      for a switch from enfuvirtide to raltegravir. At baseline, enfuvirtide was switched to
      raltegravir without additional changes to the antiretroviral regimen allowed. Viral load,
      T-cells, and toxicity were evaluated at baseline, 2, 4, 12 and 24 weeks. Adherence and
      injection site reactions were evaluated at baseline, 4, 12 and 24 weeks. The single-copy
      assay was used to measure HIV RNA levels at screening, baseline and at 12 and 24 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Patients Who Maintain a Viral Load &lt; 50 Copies/ml After Being Switched From Enfuvirtide to Raltegravir</measure>
    <time_frame>24 weeks</time_frame>
    <description>evaluate the percent of patients with viral load of &lt;50 copies at week 24 of study after being switched from enfuvirtide to raltegravir</description>
  </primary_outcome>
  <enrollment type="Actual">14</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>400 mg Twice daily for 24 weeks</description>
    <other_name>Isentress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by Western
             blot at any time prior to study entry.

          2. ART for at least 6 months prior to study entry with a regimen that includes
             enfuvirtide.

          3. Self-defined infusion site reaction to enfuvirtide (usually will be painful
             inflammatory nodules)

          4. No change in ART regimen for at least 3 months prior to study entry.

          5. CD4+ cell count &gt;50/mm3 at screening (obtained within 60 days prior to study entry).

          6. Documentation of HIV-1 RNA below the limit of quantification of an ultrasensitive
             assay

          7. All HIV-1 RNA levels obtained within 6 months prior to study entry are below the
             limits of quantification on all tests, except as explained above in section 4.1.6 for
             a single detectable viral load of &lt;50 copies but &lt;200 copies in last 6 months.

          8. Laboratory values obtained within 60 days prior to entry:

               -  Absolute neutrophil count (ANC) &gt;750/mm3

               -  Hemoglobin &gt;9.0 g/dL for female subjects and&gt;10.0 g/dL for male subjects

               -  Platelet count &gt;50,000/mm3

               -  Calculated creatinine clearance (CrCl) &gt;30 mL/min, as estimated by the
                  Cockcroft-Gault equation*

               -  AST (SGOT), ALT (SGPT), and alkaline phosphatase &lt;5 x ULN

               -  Total bilirubin &lt;2.5 x ULN. If the subject is taking an indinavir- or
                  atazanavir-containing regimen at the time of screening, total bilirubin &lt;5 x ULN
                  is acceptable.

          9. For females of reproductive potential will need a negative serum or urine pregnancy
             test within 48 hours prior to entry.

         10. Men and women age &gt;18 years.

         11. Ability and willingness of subject to provide informed consent.

        Exclusion Criteria:

          1. Unstable clinical condition, such as unstable cardiac disease, or cancer requiring
             ongoing chemotherapy or radiation therapy, or other medical condition which, in the
             opinion of the investigator, would preclude a subject from safely undergoing study
             procedures.

          2. Breast-feeding or pregnancy.

          3. An opportunistic infection within 60 days prior to entry.

          4. Known allergy/sensitivity or any hypersensitivity to components of study drug(s) or
             their formulation.

          5. Active drug or alcohol use or dependence that, in the opinion of the Protocol
             Director, would interfere with adherence to study requirements.

          6. Receipt of a non-HIV vaccination within 30 days prior to study entry or plan for
             receipt of vaccination during the study.

          7. Plan to change the background ART within 24 weeks after study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew R Zolopa</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Grant PM, Palmer S, Bendavid E, Talbot A, Slamowitz DC, Cain P, Kobayashi SS, Balamane M, Zolopa AR. Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life. J Clin Virol. 2009 Dec;46(4):305-8. doi: 10.1016/j.jcv.2009.09.025. Epub 2009 Oct 12.</citation>
    <PMID>19819183</PMID>
  </results_reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2007</study_first_submitted>
  <study_first_submitted_qc>August 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2007</study_first_posted>
  <results_first_submitted>July 20, 2011</results_first_submitted>
  <results_first_submitted_qc>September 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 28, 2011</results_first_posted>
  <last_update_submitted>October 31, 2011</last_update_submitted>
  <last_update_submitted_qc>October 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Fourteen patients, all men, were enrolled.</recruitment_details>
      <pre_assignment_details>All screened patients were enrolled into the study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Raltegravir</title>
          <description>400 mg twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Raltegravir</title>
          <description>400 mg twice daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Patients Who Maintain a Viral Load &lt; 50 Copies/ml After Being Switched From Enfuvirtide to Raltegravir</title>
        <description>evaluate the percent of patients with viral load of &lt;50 copies at week 24 of study after being switched from enfuvirtide to raltegravir</description>
        <time_frame>24 weeks</time_frame>
        <population>With expected man baseline residual viremia of 5 copies/ml and predicted standard deviation of 3 in change of residual viremia, our study was predicted to have 80% power to detect a difference of 2.5 copies/ml in residual viremia with =0.05.</population>
        <group_list>
          <group group_id="O1">
            <title>Enfuvirtide Switch to Raltegravir Arm</title>
            <description>patients were switched from Enfuvirtide to Raltegravir</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Patients Who Maintain a Viral Load &lt; 50 Copies/ml After Being Switched From Enfuvirtide to Raltegravir</title>
          <description>evaluate the percent of patients with viral load of &lt;50 copies at week 24 of study after being switched from enfuvirtide to raltegravir</description>
          <population>With expected man baseline residual viremia of 5 copies/ml and predicted standard deviation of 3 in change of residual viremia, our study was predicted to have 80% power to detect a difference of 2.5 copies/ml in residual viremia with =0.05.</population>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Raltegravir</title>
          <description>400 mg twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Philip Grant, MD</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-723-2804</phone>
      <email>pmgrant@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

